Navigation Links
UCSF collaborates with Zcube to develop new ways to deliver drugs
Date:2/28/2011

A pill filled with microscopic, drug-laden adhesive patches is at the center of an agreement between UCSF and Zcube srl, the research corporate venture arm of Italian pharmaceutical leader Zambon Co., SpA, to license UCSF-developed microtechnology and support early research into new ways to deliver oral medications directly to a targeted site in the body.

This is the first sponsored research agreement between Zcube and UCSF, but is expected to be one of several such agreements with the biomedical university.

Sponsored research agreements underscore UCSF's commitment to finding innovative ways to bridge the gap between basic research and real-world applications. They reflect continued efforts by the UCSF Office of Technology Management and Industry Contracts Division to help faculty research efforts bear fruit, while protecting the academic freedom and basic research for which UCSF is widely known.

The initial two-year agreement will support research in the UCSF Desai Laboratory into delivering drugs directly to the small intestine and colon. The exclusive, worldwide license agreement will offer milestone payments and royalties for a UCSF-patented microdevice developed by the Desai Laboratory to deliver medications for various diseases, including colitis and irritable bowel syndrome.

"This partnership is unusual because it goes beyond licensing a technology, to fund early-stage innovation in drug delivery systems," said Tejal Desai, PhD, a professor of Bioengineering and Therapeutic Sciences in the UCSF School of Pharmacy. "That research is exactly what we need to do to see whether these systems will work."

The microdevice resembles a tiny, square Band-Aid with reservoirs in the middle for medication. Hundreds of these structures, each as wide as a human hair, would be packaged into a normal-sized pill, which would break down and release them into the intestine. The micropads would then stick onto the gastro-intestinal tract and deliver medications directly into the intestinal lining, then dissolve.

As a result, Desai said, the device has the potential of targeting the colon directly and increasing drug safety by reducing the amount of medication required in each dose. When properly targeted to other intestinal areas, the device also can significantly increase the amount of medication that reaches a patient's bloodstream.

Innovative technology that markedly improves both existing medication and new therapeutic agents is a key focus for Zcube, according to Zcube General Manager Lorenzo Pradella, PhD.

"The technology Zcube licensed from UCSF is a fantastic innovation for the oral delivery of single and multiple therapies into the gastro-intestinal tract, being extremely beneficial to many patients for different diseases," Pradella said. "It confirms Zcube's efforts to support emerging life science technologies that can improve health into the future."

Zcube was founded in 2003 to support emerging life science technology and research worldwide, Pradella said. Since 2007, Zcube has placed particular emphasis on drug delivery systems and medical devices in different therapeutic fields. Zcube has established collaborations to that end with universities in Europe, the United States and Israel, as well as with Mission Bay Capital and the California Institute for Quantitative Biosciences (QB3), which is headquartered on the UCSF Mission Bay campus.


'/>"/>

Contact: Kristen Bole
kristen.bole@ucsf.edu
415-502-6397
University of California - San Francisco
Source:Eurekalert

Related medicine news :

1. PeopleStreme Collaborates with SkillSoft for Learning Management Content
2. Eisner USA, LLC Collaborates with Surgical Review Corp to Provide Innovative Bariatric Devices to Bariatric Surgery Center of Excellence (BSCOE) Participants
3. Philips Collaborates with Microsoft to Enhance Healthcare Efficiencies and Productivity
4. QB3 Adds Zcube As Limited Partner In Mission Bay Capital Fund
5. Team delivers development aid via cell phone animations
6. Top scientists unite to develop global scientific strategy Towards An HIV Cure
7. Family planning programs have success in developing countries, but need to be expanded
8. Cost-effectiveness research needs to be considered in developing new medical technology
9. Delivery Even a Bit Early May Mean Developmental Delays
10. Higher levels of social activity decrease the risk of developing disability in old age
11. Researchers develop outline that may help weigh benefits of new imaging technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Northridge dentists, ... treatments for sleep apnea and TMJ at their office. TMJ, or temporomandibular joint ... the obstructive type, is increasingly being treated at dental offices with newly developed ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, located in Southlake, ... leads programs. , In February, 2017, Empower Brokerage introduced their new “Performance Partners” ... designed to teach how to maximize their sales efforts, as well as how ...
(Date:3/24/2017)... ... ... “The Communion of Saints: A Pastor’s Potpourri of Parishioners”: ... the United States. “The Communion of Saints” is the creation of published ... in seven states throughout his long career of devotion to the church. In ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... their communities, 16 more public health departments have been awarded national accreditation through ... 4.5 million people into the expanding network of communities across the nation whose ...
(Date:3/23/2017)... ... , ... 82% of adults are unaware of the dangers that infectious bacteria play in mouth ... two times a day that dentists recommend. The ramifications of improper oral upkeep go far ... adults missing 164 million hours of work each year due to dental issues. That is ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , March 23, 2017 The ... ageing population, increasing diabetic population, accelerating economic growth and increasing ... this industry are higher life expectancy of ESRD patients, rising ... emerging markets. However, the expansion of the market is hindered ... ...
(Date:3/23/2017)... and INDIANAPOLIS , March 23, ... LLY ) and the William Sansum Diabetes Center have ... Latino people affected by diabetes through enhanced research, education ... diabetes and cardiovascular disease bears a disproportionate weight on ... ," said David Kerr , M.D., FRCPE, director ...
(Date:3/23/2017)... 2017   BioSpace , the leading biotechnology and ... Indiana Biosciences Research Institute and over 20 ... institutions to bring the state,s life sciences industry to ... an artistic representation of the region,s booming biotechnology and ... President Mike Pence , a long-time advocate of ...
Breaking Medicine Technology: